CHRS Logo

Coherus BioSciences, Inc. (CHRS) 

NASDAQ
Market Cap
$124.43M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
481 of 774
Rank in Industry
255 of 432

Largest Insider Buys in Sector

CHRS Stock Price History Chart

CHRS Stock Performance

About Coherus BioSciences, Inc.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab …

Insider Activity of Coherus BioSciences, Inc.

Over the last 12 months, insiders at Coherus BioSciences, Inc. have bought $0 and sold $449,770 worth of Coherus BioSciences, Inc. stock.

On average, over the past 5 years, insiders at Coherus BioSciences, Inc. have bought $49,668 and sold $7.99M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,700 shares for transaction amount of $49,668 was made by Stilwell McDavid (Chief Financial Officer) on 2021‑06‑09.

List of Insider Buy and Sell Transactions, Coherus BioSciences, Inc.

2023-11-22SalePresident & CEO
223,100
0.2098%
$2.02$449,770+2.74%
2021-10-15SaleChief Financial Officer
3,507
0.0045%
$16.80$58,919-30.65%
2021-09-29Saledirector
286,076
0.3546%
$16.12$4.61M-26.09%
2021-09-28Saledirector
48,329
0.0622%
$17.17$829,809-27.59%
2021-09-27Saledirector
100,150
0.1287%
$18.06$1.81M-30.86%
2021-06-09PurchaseChief Financial Officer
3,700
0.0049%
$13.42$49,668+0.96%
2021-06-08SalePresident & CEO
31,054
0.0411%
$13.56$421,229+0.59%
2021-03-09SaleChief Scientific Officer
114,240
0.1583%
$16.25$1.86M-9.44%
2021-03-05SaleChief Operating Officer
26,649
0.0357%
$15.46$412,065-7.55%
2021-02-17SaleChief Operating Officer
2,488
0.0034%
$17.45$43,418-13.71%
2021-02-01SaleChief Financial Officer
7,402
0.0124%
$21.55$159,513-13.35%
2021-01-25SaleChief Financial Officer
46,144
0.0647%
$19.95$920,736-21.18%
2021-01-19SaleChief Operating Officer
2,500
0.0034%
$17.94$44,852-13.26%
2020-12-17SaleChief Operating Officer
2,500
0.0034%
$17.51$43,780-10.94%
2020-12-10SaleChief Scientific Officer
17,626
0.0246%
$18.05$318,066-11.68%
2020-12-09SaleChief Scientific Officer
49,512
0.0685%
$18.24$903,084-13.28%
2020-12-07SaleChief Operating Officer
8,791
0.0122%
$18.42$161,896-13.80%
2020-12-04SaleChief Operating Officer
49,000
0.0675%
$18.85$923,694-16.42%
2020-12-03SaleChief Operating Officer
49,756
0.0692%
$18.67$929,079-14.87%
2020-11-18SaleChief Operating Officer
4,283
0.006%
$18.00$77,094-11.09%

Insider Historical Profitability

55.38%
LILLY ELI & CO
3042019
2.6403%
$1.0810+82.59%
Stilwell McDavidChief Financial Officer
31611
0.0274%
$1.0811+0.96%
HEALY JAMESdirector
0
0%
$1.0818+82.59%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$26.84M9.7911.23M-6.99%-$2.02M<0.01
Helm Capital Management LLC$24.86M9.0710.4M+2,531.53%+$23.91M0.74
The Vanguard Group$24.09M8.7910.08M-2.68%-$664,080.62<0.0001
Temasek Holdings$17.64M6.437.38M0%+$00.1
Kohlberg Kravis Roberts$7.26M2.653.04M0%+$00.23
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.